Vilin Bio Med Limited (NSEI: VILINBIO)
Health Care · Pharmaceuticals · IN
Rs43.50
-1.25% today · +70.6% 1Y
Vilin Bio Med Limited (NSEI: VILINBIO) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $6.35M and employs 14 people.
Over the last twelve months the share price has gained 70.6%, trading between 18.95 and 54.40.
Tweenvest scores Vilin Bio Med Limited across four factors: quality 64/100, value 64/100, growth 86/100. Its strongest factor is growth.
VILINBIO price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $6.35M
- Revenue (TTM)
- $4.51M
- P/E
- 31.75
- EPS
- 1.37
- Dividend yield
- —
- Beta (5Y)
- 0.66
- 52-week high
- Rs54.40
- 52-week low
- Rs18.95
- Avg volume (3M)
- —
- Shares outstanding
- 13.95M
- Employees
- 14
- Next earnings
- —
About Vilin Bio Med Limited
Vilin Bio Med Ltd. is a domestic pharmaceutical company primarily engaged in the manufacturing and trading of pharmaceutical products, with a focus on generic formulations across various therapeutic segments. The company produces pharmaceutical formulations such as oral liquids, dry syrups, sachets, external preparations, beta and non-beta lactam tablets and capsules, and nutritional food supplements. These products address therapeutic areas including anti-infectives, analgesics, cardiovascular, musculoskeletal, antibiotic, central nervous system, alimentary system, genito-urinary tract, respiratory system, anti-allergic, and anti-diabetic conditions. Vilin Bio Med also engages in contract manufacturing and the distribution of its own branded generics, supplying products in bulk to pharmaceutical manufacturers, marketers, and traders. Beyond pharmaceuticals, the company offers a range of cosmetics, including products for baby care, skin care, oral care, and hair care, such as serums, oils, lotions, creams, cleansers, moisturizers, and masks. The primary target market for Vilin Bio Med is the domestic Indian market, which generates over 90% of its revenue, though it also has international operations and a U.S. subsidiary for marketing and distribution in the United States, alongside a presence in GCC, Africa, EU, and Asia.
- ISIN
- INE0L4V01013
- Founded
- 2005
- Listed since
- Jun 30, 2023
- Exchange
- National Stock Exchange of India
- Currency
- INR
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.10T | $1,235.35 | +0.14% |
| Johnson & JohnsonNYSE: JNJ | $658.24B | $273.38 | +0.09% |
| Merck & Co., Inc.NYSE: MRK | $385.99B | $156.17 | -0.18% |
| Roche Holding AGSWX: ROP | $371.62B | CHF374.20 | +0.11% |
| Novartis AGSWX: NOVN | $303.81B | CHF128.34 | +1.25% |
| AstraZeneca PLCLSE: AZN | $263.84B | £123.68 | -0.87% |
| Novo Nordisk A/SCPSE: NOVO B | $212.51B | Dkr307.80 | +2.86% |
| Pfizer Inc.NYSE: PFE | $162.84B | $28.51 | -0.21% |
Figures last refreshed Aug 18, 2026.